Images List Premium Download Classic

Pharmaceutically Acceptable Salt

Pharmaceutically Acceptable Salt-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
NEW Compounds, linker-drugs and ligand-drug conjugates
Industrial Technology Research Institute
January 18, 2018 - N°20180016300

A compound of formula (i) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (i), r1, r2 and r3 are each, independently, hydrogen, amino, nitro, halogen, hydroxyl, c1-c6 alkoxy, carboxylic acid, c1-c6 alkoxycarbonyl, c1-c6 amino, c1-c6 aminocarbonyl, c1-c6 alkyl, branched c1-c6 alkyl, c1-c6 cycloalkyl, c1-c6 heterocyclic, aryl or heteroaryl, ...
NEW Deuterated tic10
Concert Pharmaceuticals, Inc.
January 18, 2018 - N°20180016277

This invention relates to novel imidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one compounds, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions alone or in combination with other therapeutics in the treatment of diseases and conditions that are beneficially treated by administering an inducer of the gene ...
NEW Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
Scifluor Life Sciences, Inc.
January 18, 2018 - N°20180016276

The invention relates to fluorinated compounds and their use as integrin receptor antagonists. Novel fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives and pharmaceutically acceptable salts or solvates thereof and their use are described.
NEW Pharmaceutically Acceptable Salt Patent Pack
Download 1713+ patent application PDFs
Pharmaceutically Acceptable Salt Patent Applications
Download 1713+ Pharmaceutically Acceptable Salt-related PDFs
For professional research & prior art discovery
inventor
  • 1713+ full patent PDF documents of Pharmaceutically Acceptable Salt-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Kappa opioid agonists and uses thereof
January 18, 2018 - N°20180016266

And pharmaceutically acceptable salts and solvates thereof, wherein r1, r2, r3, r4, r5, and r6 are as described herein. The compounds of formula i are agonists of the kappa opioid receptor and relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.
NEW Inhibitors of the renal outer medullary potassium channel
Merck Sharp & Dohme Corp.
January 18, 2018 - N°20180016263

The present invention provides compounds of formula (i); and the pharmaceutically acceptable salts thereof, which are inhibitors of the romk (kir1. 1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt ...
NEW 2-(2,4,5-substituted aniline) pyrimidine derivative, pharmaceutical composition and use thereof
Changzhou Runnor Biological Technology Co., Ltd
January 18, 2018 - N°20180016258

Disclosed are a 2-(2,4,5-substituted aniline) pyrimidine derivative, a pharmaceutical composition and a use thereof. The pharmaceutical composition comprises a therapeutically effective amount of the 2-(2,4,5-substituted aniline) pyrimidine derivative, a solvate, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. Also disclosed is a use of the 2-(2,4,5-substituted aniline) pyrimidine derivative, a solvate, or a pharmaceutically ...
NEW Pharmaceutically Acceptable Salt Patent Pack
Download 1713+ patent application PDFs
Pharmaceutically Acceptable Salt Patent Applications
Download 1713+ Pharmaceutically Acceptable Salt-related PDFs
For professional research & prior art discovery
inventor
  • 1713+ full patent PDF documents of Pharmaceutically Acceptable Salt-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
January 18, 2018 - N°20180016255

Or a pharmaceutically acceptable salt thereof. A method of treating exacerbations of asthma and chronic obstructive pulmonary disease includes administering to a patient an effective amount of the compound or a pharmaceutically acceptable salt thereof.
NEW Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
January 18, 2018 - N°20180016254

Or a pharmaceutically acceptable salt thereof. A method of treating a respiratory tract disease includes administering to a patient an effective amount of the compound or a pharmaceutically acceptable salt thereof.
NEW New benzimidazole derivatives as antihistamine agents
Faes Farma, S.a.
January 18, 2018 - N°20180016251

The invention relates to compounds of formula (i), or a pharmaceutically acceptable salt or solvate thereof, a method of synthesis of said compounds, pharmaceutical compositions comprising them and their use in the treatment and/or prevention of conditions mediated by h1 histamine receptor, such as allergic disorders or diseases.
NEW Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
Merck Sharp & Dohme Corp.
January 18, 2018 - N°20180016239

The present invention relates to compounds according to formula (i-1) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of rorgammat-mediated diseases or conditions.
NEW Low-dose stable formulations of linaclotide
Forest Laboratories Holdings Limited
January 18, 2018 - N°20180015139

The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
NEW Process for granulating sevelamer carbonate
Amneal Pharmaceuticals Company Gmbh
January 18, 2018 - N°20180015119

The present disclosure provides a pharmaceutical composition comprising of a polyallylamine polymer or pharmaceutically acceptable salts thereof; excipient based hydrous granules and optionally moisture retaining agents. The present disclosure also provides process embodiments for preparation of the pharmaceutical compositions comprising of modified moisture activated granulation technique. Polyallylamine polymers used are sevelamer, colesevelam or pharmaceutically acceptable salts thereof, preferably sevelamer hcl, ...
NEW Pharmaceutically Acceptable Salt Patent Pack
Download 1713+ patent application PDFs
Pharmaceutically Acceptable Salt Patent Applications
Download 1713+ Pharmaceutically Acceptable Salt-related PDFs
For professional research & prior art discovery
inventor
  • 1713+ full patent PDF documents of Pharmaceutically Acceptable Salt-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Methods and compositions for improving cognitive function
The Johns Hopkins University
January 18, 2018 - N°20180015109

The invention relates to methods and compositions for improving cognitive function by using a combination of a synaptic vesicle protein 2a (sv2a) inhibitor and an acetylcholinesterase inhibitor (achei) or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In particular, it relates to the use of a combination of an sv2a inhibitor and an achei in treating a central ...
NEW Steroid compound for use in the treatment of hepatic encephalopathy
Umecrine Cognition Ab
January 18, 2018 - N°20180015103

The present invention provides the steroidal compound 3α-ethynyl-3β-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.
NEW Combination products for the treatment of bacterial infections and methods of producing or dosing of ...
Achaogen, Inc.
January 18, 2018 - N°20180015100

Provided herein are methods of treating a bacterial infection, wherein the methods comprise administering (a) ceftibuten or a pharmaceutically acceptable salt thereof, or a hydrate of the foregoing; and (b) clavulanic acid, or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions, articles of manufacture, and kits comprising a) ceftibuten or a pharmaceutically acceptable salt thereof, or a hydrate ...
NEW Site specific dosing of a btk inhibitor
Principia Biopharma Inc.
January 18, 2018 - N°20180015088

Disclosed herein are formulations and methods of site specific administration of compound (i) or a pharmaceutically acceptable salt thereof. Compound (i) is a potent btk inhibitor and hence can be useful for the treatment of diseases such as cancer, autoimmune, and inflammatory diseases.
NEW Pyridinyl and fused pyridinyl triazolone derivatives
January 18, 2018 - N°20180015083

Or pharmaceutically acceptable salts thereof, wherein r1, r2, r3, and r4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of formula 1, to pharmaceutical compositions which contain them, and to their use for treating type i hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with btk.
NEW Crenolanib for treating flt3 mutated proliferative disorders
Arog Pharmaceuticals, Inc.
January 18, 2018 - N°20180015081

The present invention relates to the use of crenolanib, in a pharmaceutically acceptable salt form for the treatment of flt3 mutated proliferative disorders driven by constitutively activated mutant flt3, and to a method of treatment of warm-blooded animals, preferably humans, in which a therapeutically effective dose of crenolanib is administered to an animal suffering from said disease or condition:
NEW Methods of increasing tonic inhibition and treating secondary insomnia
Ovid Therapeutics Inc.
January 18, 2018 - N°20180015076

Methods of increasing tonic inhibition in a subject in need thereof, for example a subject with fragile x syndrome or angelman syndrome are disclosed. Methods of treating secondary insomnia in a subject with a neurodegenerative disease or disorder are also disclosed. The methods can include administering the subject an effective amount of 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (thip) or a derivative ...
NEW Stable trientine formulations
Kadmon Pharmaceuticals, Llc
January 18, 2018 - N°20180015053

Provided are pharmaceutical dosage forms comprising (i) trientine or a pharmaceutically acceptable salt of trientine, in a (ii) sealed packaging. The sealed packaging provides a high barrier protection against air, moisture and light and prevents exposure of the drug to conditions that facilitate its decomposition. The pharmaceutical dosage forms are useful for treating diseases or conditions where excess copper is ...
Loading